The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines™ is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.
© National Comprehensive Cancer Network, Inc. 2011, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
Disclosures for the NCCN Guidelines Panel for Kidney Cancer
At the beginning of each NCCN Guidelines panel meeting, panel members disclosed any financial support they have received from industry. Through 2008, this information was published in an aggregate statement in JNCCN and online. Furthering NCCN's commitment to public transparency, this disclosure process has now been expanded by listing all potential conflicts of interest respective to each individual expert panel member.
Individual disclosures for the NCCN Guidelines for Kidney Cancer panel members can be found on page 977. (The most recent version of these guidelines and accompanying disclosures, including levels of compensation, are available on the NCCN Web site at www.NCCN.org.)
These guidelines are also available on the Internet. For the latest update, visit www.NCCN.org.
Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002;11:37–42.
DeVita VT Jr, Hellman S, Rosenberg SA. Cancer Principles and Practice of Oncology. 8th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
Horner MJ, Ries LA, Krapcho M et al.. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2006/. Accessed June 21, 2011.
Hricak H, Demas BE, Williams RD et al.. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology 1985;154:709–715.
Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diagn Imaging 1991;32:69–118.
Blom JH, van Poppel H, Marechal JM et al.. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009;55:28–34.
Blute ML, Leibovich BC, Cheville JC et al.. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 2004;172:465–469.
Kuczyk M, Munch T, Machtens S et al.. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int 2002;89:517–522.
Kuczyk M, Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol 2005;48:252–257.
O’Malley RL, Godoy G, Kanofsky JA, Taneja SS. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J Urol 2009;181:2009–2017.
Hollingsworth JM, Miller DC, Dunn RL et al.. Surgical management of low-stage renal cell carcinoma: Technology does not supersede biology. Urology 2006;67:1175–1180.
Leibovich BC, Blute ML, Cheville JC et al.. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;171:1066–1070.
Shuch B, Lam JS, Belldegrun AS. Open partial nephrectomy for the treatment of renal cell carcinoma. Curr Urol Rep 2006;7:31–38.
Chen DY, Uzzo RG. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw 2009;7:635–642; quiz 643.
Dash A, Vickers AJ, Schachter LR et al.. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int 2006;97:939–945.
Lau WK, Blute ML, Weaver AL et al.. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000;75:1236–1242.
Lee CT, Katz J, Shi W et al.. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol 2000;163:730–736.
Huang WC, Levey AS, Serio AM et al.. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006;7:735–740.
Go AS, Chertow GM, Fan D et al.. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.
Weight CJ, Lieser G, Larson BT et al.. Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol 2010;58:293–298.
Weight CJ, Larson BT, Gao T et al.. Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology 2010;76:631–637.
Funahashi Y, Hattori R, Yamamoto T et al.. Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. Eur Urol 2009;55:209–215.
Rais-Bahrami S, Guzzo TJ, Jarrett TW et al.. Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. BJU Int 2009;103:1355–1358.
Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer 2008;113:2671–2680.
Clark JI, Atkins MB, Urba WJ et al.. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003;21:3133–3140.
Messing EM, Manola J, Wilding G et al.. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003;21:1214–1222.
Trump D, Elson P, Propert K et al.. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L IFN) in resected, high risk renal cell carcinoma (HR-RCC) [abstract]. Proc Am Soc Clin Oncol 1996;15:Abstract 648.
Lam JS, Shvarts O, Leppert JT et al.. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005;174:466–472; discussion 472; quiz 801.
- Search Google Scholar
- Export Citation
. Lam JS Shvarts O Leppert JT Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005; 174: 466– 472; discussion 472; quiz 801.
Flanigan RC, Mickisch G, Sylvester R et al.. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–1076.
Flanigan RC, Salmon SE, Blumenstein BA et al.. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655–1659.
Mickisch GH, Garin A, van Poppel H et al.. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966–970.
Polcari AJ, Gorbonos A, Milner JE, Flanigan RC. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Int J Urol 2009;16:227–233.
Culp SH, Tannir NM, Abel EJ et al.. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010;116:3378–3388.
Leibovich BC, Han KR, Bui MH et al.. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:2566–2575.
Rosenberg SA, Mule JJ, Spiess PJ et al.. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:1169–1188.
Dutcher JP, Fisher RI, Weiss G et al.. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157–162.
Negrier S, Escudier B, Lasset C et al.. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 1998;338:1272–1278.
Fyfe G, Fisher RI, Rosenberg SA et al.. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688–696.
McDermott DF, Regan MM, Clark JI et al.. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133–141.
Motzer RJ, Hutson TE, Tomczak P et al.. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584–3590.
Yang JC, Sherry RM, Steinberg SM et al.. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127–3132.
Motzer RJ, Bacik J, Murphy BA et al.. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289–296.
Leibovich BC, Blute ML, Cheville JC et al.. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:1663–1671.
Motzer RJ, Hutson TE, Tomczak P et al.. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–124.
Motzer RJ, Michaelson MD, Redman BG et al.. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16–24.
Faivre S, Delbaldo C, Vera K et al.. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25–35.
Gore ME, Szczylik C, Porta C et al.. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757–763.
Escudier B, Pluzanska A, Koralewski P et al.. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103–2111.
Rini BI, Choueiri TK, Elson P et al.. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 2008;113:1309–1314.
Rini BI, Halabi S, Rosenberg JE et al.. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137–2143.
Sternberg CN, Davis ID, Mardiak J et al.. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061–1068.
Hudes G, Carducci M, Tomczak P et al.. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–2281.
Awada A, Hendlisz A, Gil T et al.. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855–1861.
Clark JW, Eder JP, Ryan D et al.. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472–5480.
Moore M, Hirte HW, Siu L et al.. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688–1694.
- Search Google Scholar
- Export Citation
. Moore M Hirte HW Siu L Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16: 1688– 1694.
Strumberg D, Richly H, Hilger RA et al.. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965–972.
Wilhelm SM, Carter C, Tang L et al.. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–7109.
Escudier B, Szczylik C, Hutson TE et al.. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280–1289.
Motzer RJ, Escudier B, Oudard S et al.. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–456.
Motzer RJ, Escudier B, Oudard S et al.. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256–4265.
Eisen T, Bukowski RM, Staehler M et al.. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 4524.
Bukowski RM, Eisen T, Szczylik C et al.. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 5023.
Dudek AZ, Zolnierek J, Dham A et al.. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115:61–67.
Eichelberg C, Heuer R, Chun FK et al.. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008;54:1373–1378.
Heuer R, Eichelberg C, Zacharias M, Heinzer H. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib [abstract]. Eur Urol Suppl 2009;8:183. Abstract 251.
Sablin MP, Bouaita L, Balleyguier C et al.. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients [abstract]. J Clin Oncol 2007;25:Abstract 5038.
Sablin MP, Negrier S, Ravaud A et al.. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009;182:29–34; discussion 34.
Shepard DR, Rini BI, Garcia JA et al.. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [abstract]. J Clin Oncol 2008;26:Abstract 5123.
Zimmermann K, Schmittel A, Steiner U et al.. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009;76:350–354.
Dutcher JP, de Souza P, McDermott D et al.. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26:202–209.
Gordon MS, Hussey M, Nagle RB et al.. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27:5788–5793.
Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol, in press.
Nanus DM, Garino A, Milowsky MI et al.. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:1545–1551.
Haas N, Manola J, Pins M et al.. ECOG 8802: phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features [abstract]. Presented at the ASCO Genitourinary Cancers Symposium 2009; February 26–28, 2009; Orlando, Florida. Abstract 285.
- Search Google Scholar
- Export Citation
. Haas N Manola J Pins M ECOG 8802: phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features [abstract]. Presented at the ASCO Genitourinary Cancers Symposium 2009; February 26–28, 2009; Orlando, Florida. Abstract 285.
Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98:962–969.
Rosen LS, Gordon D, Tchekmedyian NS et al.. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613–2621.
- Search Google Scholar
- Export Citation
. Rosen LS Gordon D Tchekmedyian NS Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613– 2621.